drugset / Trial / NCT04239014

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

NCT04239014

Phase 2 Withdrawn AstraZeneca Parexel · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate the effectiveness and tolerability of a second maintenance treatment in participants with platinum-sensitivity relapsed (PSR) epithelial ovarian cancer, who have previously received PARPi maintenance treatment and who have benefit (complete response \[CR\] or partial response \[PR\]) or stable disease (SD) from further platinum based chemotherapy.

Timeline

Start
2020-08-07
Primary completion
2021-01-25
Completion
2021-01-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Ceralasertib Small molecule 160 mg Oral
Subject Olaparib Small molecule 300 mg Oral

Indications